The results from the tests were presented at the 16th International Prostate Cancer Update Conference in Beaver Creek, Colorado, and suggested that the drug may induce slow pan-cell cycle progression and mitotic commitment with a limited expression of G2 arrest.
“Alchemix possesses potent activity across a variety of chemotherapy-resistant human tumors, including prostate cancer,” said Dr Agamemnon Epenetos president and CEO of Somanta. “The study suggests that this effect is probably due to the pan-cell cycle effects, and specifically that multi-level targeting by Alchemix reduces the probability of cancer cells surviving even if they are resistant to other chemotherapy drugs.”